Liminatus Pharma Faces Nasdaq Delisting, Plans to Appeal
Liminatus Pharma notifies Nasdaq of impending delisting; plans to appeal
Image: Seeking Alpha
Liminatus Pharma (LIMN) has received a delisting notice from Nasdaq due to non-compliance with its listing rules, specifically failing to meet the market value requirements. The company plans to appeal the decision, seeking to maintain its listing status.
- 01Liminatus Pharma received a delisting notice from Nasdaq on May 20, 2026.
- 02The company failed to meet the $50,000,000 market value of listed securities requirement.
- 03Liminatus also did not comply with the $15,000,000 market value of publicly held shares requirement.
- 04The company intends to appeal the delisting notice before a Nasdaq panel.
- 05This situation highlights ongoing challenges for Liminatus Pharma in maintaining its market presence.
Advertisement
In-Article Ad
Liminatus Pharma (LIMN) announced on Friday that it has received a delisting notice from Nasdaq due to its failure to regain compliance with the exchange's continued listing rules. Specifically, the company did not meet the requirements for a minimum market value of listed securities, which is set at $50,000,000, and a minimum market value of publicly held shares, which is $15,000,000. In response to the notice, Liminatus Pharma plans to appeal the decision to a Nasdaq panel, aiming to retain its listing status and address the compliance issues that led to the notice.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you think Liminatus Pharma will successfully appeal the delisting?
Connecting to poll...
More about Liminatus Pharma
Read the original article
Visit the source for the complete story.